Navigation Links
Therapeutic Cancer Vaccine Trials

Ongoing therapeutic cancer vaccine trials have yet to show evidence of vaccines spurring a patients immune system to shrink tumors -- yet patients who receive these vaccines in trials tend to live longer and respond better to subsequent treatment.

In the July 1 issue of Clinical Cancer Research, a journal of the American Association for Cancer Research, a team of National Cancer Institute researchers asks a fundamental question: are we looking at cancer vaccine trials the wrong way".

In a review of five prostate cancer vaccine trials, NCI researchers offer evidence that patients who receive vaccines may respond better to subsequent chemotherapy or hormone treatment.

The specific results or endpoints of these clinical trials, however, were not the long term survival of patients, but rather the degree to which the vaccine caused tumors to shrink. According to the researchers, since they didnt achieve their primary endpoints, these vaccines may be abandoned as dead-ends, despite their real therapeutic value in terms of prolonging patient survival.

Clinical data are providing evidence that patients are living longer following vaccination, de-spite the fact that trials do not show the vaccines can induce the immune system into shrinking tumors, said Jeffrey Schlom, Ph.D., chief of the Laboratory of Tumor Immunology and Biology at the National Cancer Institute.

The data suggests that the scientific community and regulatory committees ought to rethink the design of clinical vaccine trials and our current approach to measuring the effectiveness of a cancer vaccine.

According to the researchers, it may be more helpful to think of the effectiveness of a vaccine in terms of the response of the patient, rather than the response of the tumor.

While the Response Criteria in Solid Tumors (RECIST) experimental standards works well in evaluating therapies that are toxic to tumors, s uch as radiation or chemotherapy, they are less capable of measuring the more subtle systemic effects of immune response, Schlom said.

While there is no conclusive evidence to explain why a vaccine may lead to better patient sur-vival, Schlom believes the evidence suggests that vaccines are, in fact, priming the immune sys-tem. Vaccines are not passive, they induce a dynamic process of immune response that, in many cases may keep the tumor in check and enhance the effectiveness of subsequent therapies, Schlom said.

About Therapeutic Cancer Vaccines Unlike preventative vaccines, like those that protect against human papillomavirus or the flu, therapeutic cancer vaccines are given in the hopes of treating an existing disease.

These cancer vaccines generally fall into two categories: cell-based, where vaccines are created using cells from the patients own immune system that have been activated to the presence of cancer antigens and delivered back to the patient along with additional proteins that facilitate immune activation; and vector-based, where an engineered virus, or vector, is used to introduce cancer proteins and other molecules to stimulate the immune system. Both approaches are designed to rile the patients immune system into attacking tumor cells.

In their review Schlom and his colleagues looked at two cell-based vaccines, Sipuleucel-T (Provenge) and GVAX, as well as three trials using an engineered pox-virus vector. While this review article focuses on prostate cancer vaccines, the researchers consider these trials as exam-ples of ongoing progress in similar vaccine therapies for lymphoma, melanoma, pancreatic, lung and other types of cancer.


'"/>




Related medicine news :

1. Understanding Chronic Infections May Help in Developing Therapeutic Vaccines
2. Therapeutic cloning by regenerating stem cells from heart muscles
3. Therapeutic Genes Transferred By Viral Vector Through T Cell Masking
4. Therapeutic Monoclonal Antibody Production Is More Profitable Than Small Molecule Drugs
5. Functional Differences In Estrogen Receptor Could Be A Therapeutic Target
6. Clinical-trials Show Increased Therapeutic Activity of Pycnogenol than Daflon
7. Safety of Cancer Therapeutic Viruses Enhanced
8. Researchers Enhance Safety and Effectiveness of Therapeutic Virus that Fights Cancer
9. Human Embryonic Stem Cells Could Be Later Used In Therapeutic Cloning
10. Contemporary Therapeutic Guidelines For HIV Patients
11. Potential New Therapeutic Target for Asthma, Allergies and Cancer
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/23/2017)... ... March 23, 2017 , ... ChenMed, a privately ... completion of the strategic executive team expansion needed to further optimize growth and ... executive team,” says Christopher Chen, MD, ChenMed Chief Executive Officer. “George Wheeler ...
(Date:3/23/2017)... ... March 23, 2017 , ... Inflow IQ & Inflownomics of Raleigh, ... build on a solid foundation. As experts in dangerous situations the Inflow IQ ... coming soon. Inflownomics deliver ripe, fresh, clean & refreshing knowledge systems that enhance life. ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... Force Dagger Foundation the US Special Operations Command’s Patriot Award. The award was ... Thomas thanked Task Force Dagger Foundation for its significant and enduring support to ...
(Date:3/23/2017)... ... 23, 2017 , ... “Beyond and Back”: a true-life testimony of tragedy and ... published author Bonetta Rose, a wife, mother and grandmother committed to sharing her many ... Publishing, Bonetta Rose‘s new book presents actual events in the life of her family, ...
(Date:3/23/2017)... ... March 23, 2017 , ... “The Trainer”: an ... published author, Scotty, a fiction writer with an active imagination and an enthusiasm for ... book follows the tale of Wild Bill Hart, who sat looking at the thirty-three ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... , March 23, 2017 CENTRO DE ... article 157, paragraph 4 of Law 6,404/76 and Instruction ... hereby informs its shareholders and the market in general ... its subsidiary Centro de Diagnosticos por Imagem Ltda. (" ... 100% interest in RADIOLOGISTAS ASSOCIADOS LTDA. (" Partnership " ...
(Date:3/23/2017)... 2017 Ascendis Pharma A/S (Nasdaq: ASND), a ... address significant unmet medical needs in rare diseases, today ... and webcast on Monday, April 3 during ENDO 2017, ... Orlando, Florida , to discuss new data ... Hormone, TransCon PTH and TransCon CNP). Ascendis ...
(Date:3/23/2017)... - INVICTUS MD STRATEGIES CORP. ("Invictus MD" or the "Company") ... that AB Laboratories Inc. ("AB Labs") has successfully completed ... the Access to Cannabis for Medical Purposes Regulations ("ACMPR") ... The facility, which was licensed for Cultivation ... at half capacity, with full production capacity scheduled by ...
Breaking Medicine Technology: